Pathology Against the Clock: Verification of Gene Expression Subtyping for the GUSTO Clinical Trial

Published in Journal of Pathology, 2023

Background: Neoadjuvant chemotherapy (NAC) prior to radical cystectomy is standard of care for muscle invasive bladder cancer (MIBC). Currently this approach is offered to all eligible patients however recent studies that classified MIBC by gene expression signatures indicate that the response to NAC may vary by subtype. Gene expression subtypes of Urothelial cancer: Stratified Treatment and Oncological outcomes (GUSTO) is a multicentre, prospective, open-label, individually randomised, controlled, parallel-group, multi-stage phase II trial of patients with T2-4a N0 M0 MIBC or T(any) N1 M0 MIBC who are suitable for NAC with cisplatin and gemcitabine prior to radical cystectomy. GUSTO will assess if gene expression subtype guided care is feasible within current clinical pathways.

Methods: RNA was extracted from 18 archival formalin fixed paraffin embedded (FFPE) blocks containing MIBC. Gene expression was analysed using GeneChip Microarrays and samples assigned TCGA subtypes. Samples were analysed twice on different days and in different batches to assess technical reproducibility. Quality control metrics, subtype concordance between technical replicates and turn-around time were assessed.

Results: Adequate quality and quantity of RNA was extracted from all blocks. All samples passed wet-lab and bioinformatics quality control. All subtypes were represented within the cohort (basal: 10; luminal-papillary: 3; luminal: 2; luminal-infiltrated: 2; neuronal: (1). Subtype was concordant between technical replicates in 17/18 samples. One sample changed from luminal-papillary to luminal subtype; this would not affect treatment assignment within GUSTO. All samples were processed within 8 days.

Conclusion: TCGA2 subtyping of MIBC can be reliably and robustly performed in a clinically useful timeframe.